


Supplementary material for Spindler et al., Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma, Acta Oncologica, 2013;52:963–970.

Supplementary Table I. Primer and probe sequences for DNA and **KRAS** mutational detection.


Name	Type	Sequence	Final concentration
gCYC	Forward	ACATGGGTACTAAGCAACAAAATAAG	300 nM
	Reverse	CACAATTGGAACATCTTTGTTAAAC	300 nM
	Probe	Fam-TTGCAGACAAGGTCCCAAAGACAGCA-Tamra	200 nM
12Ala	Forward	ACCTTATGTGTGACATGTTCTAATATAGT	300 nM
	Reverse	GCACTCTTGCCTACGCGAG	300 nM
	Probe	Fam-CCTGCTGAAAATGACTGAATATAAACTTGTGG-Tamra	200 nM
12Arg	Forward	ACCTTATGTGTGACATGTTCTAATATAGT	300 nM
	Reverse	CACTCTTGCCTACGCGCTCG	300 nM
	Probe	Fam-CCTGCTGAAAATGACTGAATATAAACTTGTGG-Tamra	200 nM
12Asp	Forward	ACCTTATGTGTGACATGTTCTAATATAGT	300 nM
	Reverse	GCACTCTTGCCTACGCGAT	300 nM
	Probe	Fam-CCTGCTGAAAATGACTGAATATAAACTTGTGG-Tamra	200 nM
12Cyc	Block	CCTACGCCACCAGCT (with 4 pentabases)	1000 nM
	Forward	ACCTTATGTGTGACATGTTCTAATATAGT	300 nM
	Reverse	CACTCTTGCCTACGCCGCA	300 nM
12Ser	Probe	Fam-CCTGCTGAAAATGACTGAATATAAACTTGTGG-Tamra	200 nM
	Block	CCTACGCCACCAGCT (with 4 pentabases)	1000 nM
	Forward	CTTATGTGTGACATGTTCTAATATAGT	300 nM
12Val	Reverse	CACTCTTGCCTACGCCCT	300 nM
	Probe	Fam-CCTGCTGAAAATGACTGAATATAAACTTGTGG-Tamra	200 nM
	Block	CCTACGCCACCAGCT (with 4 pentabases)	1000 nM
13Asp	Forward	ACCTTATGTGTGACATGTTCTAATATAGT	300 nM
	Reverse	GCACTCTTGCCTACGCGAA	900 nM
	Probe	Fam-CCTGCTGAAAATGACTGAATATAAACTTGTGG-Tamra	200 nM
13Asp	Forward	ACCTTATGTGTGACATGTTCTAATATAGT	300 nM
	Reverse	TCAAGGCACTCTTGCCTATGT	300 nM
	Probe	Fam-CCTGCTGAAAATGACTGAATATAAACTTGTGG-Tamra	200 nM
13Asp	Block	CTTGCCTACGCCACCA (with 4 pentabases)	1000 nM

64 patients



55 included in the survival analysis

64 patients



50 available for correlation of *pKRAS* with efficacy

Figure 1. Supplementary Sample size for biomarker correlation with outcome.